- FDA approves CosACTHen® as the first canine-specific cosyntropin injection in the U.S.
- Product is indicated for evaluating adrenal function in dogs.
- CosACTHen® supports ACTH stimulation testing for Cushing’s and Addison’s disease.
- Dechra says the approval strengthens its veterinary endocrinology portfolio.
- Product will be available in 0.25 mg/ml single-use vials for IV or IM administration.
Dechra has announced FDA approval of CosACTHen® (cosyntropin injection), marking the first and only cosyntropin product specifically indicated for canine patients in the United States. The approval expands diagnostic options for veterinarians managing endocrine disorders in dogs, particularly Cushing’s disease and Addison’s disease.
The product is indicated for evaluating adrenal function in dogs and is intended for use in ACTH stimulation testing, which is commonly used to confirm Addison’s disease and assist in diagnosing and monitoring Cushing’s disease. The company said CosACTHen® can also support monitoring protocols for dogs receiving Vetoryl® (trilostane).
Focus on Endocrine Diagnostics
According to Dechra, CosACTHen® will be supplied as a 0.25 mg/ml solution in 1 ml single-use vials and can be administered intravenously or intramuscularly. Veterinarians measure baseline and post-stimulation cortisol levels to assess adrenal function following administration.
“We know how challenging endocrine diagnoses can be,” said Dr. Jill Stohs, senior director of veterinary professional services and medical affairs at Dechra, in the company announcement. “With CosACTHen®, veterinarians can now have the confidence of performing ACTH stimulation tests with the first and only FDA-approved cosyntropin designed specifically for canine patients.”
The company also highlighted storage convenience, noting the refrigerated product is intended to be readily available for urgent endocrine cases.
Expanding Specialty Support
Dechra said the approval reinforces its investment in veterinary endocrinology and specialty support services. The company reported conducting more than 1,200 Cushing’s-related case consultations during the previous 12-month reporting period through its Veterinary Technical Services team.
In addition to the product launch, Dechra stated that veterinary teams will continue to have access to technical consultations and endocrine-focused support resources.
Information sourced from Dechra’s company press release.
